Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Go back to Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 288.18 +1.77 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $286.41 | 52 Week High | $109.10 | |||
| Open | $290.89 | 52 Week Low | $31.38 | |||
| Day High | $291.95 | P/E | N/A | |||
| Day Low | $285.26 | EPS | $-1.45 | |||
| Volume | 1,087,832 | |||||
